Genentech Inc.is once again looking for FDA approval for a metastatic breast cancer therapy based on impressive progression-free survival data from a single trial. But the company maintains that the pertuzumab application will not run into the same difficulties as Avastin.
For one thing, the BLA submission is for full approval, not going through the accelerated approval program that led to...